Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Inhibition of CDK Activity

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Total Cranial Vault Remodeling Using Multidirectional Cranial Distraction Osteogenesis in Craniosynostosis.

Plastic and reconstructive surgery. Global open·2026

Same author

Impact of breast cancer surgical procedures on postoperative daily life: a multicenter patient-reported outcomes study.

International journal of clinical oncology·2026

Same author

Factors influencing surgical decision-making in breast cancer: A multicenter study in Japan.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026

Same author

Mesenchymal stromal cell-derived extracellular vesicles in regenerative medicine: Standardisation, bioengineering and clinical translation.

Regenerative therapy·2026

Same author

Risk Factors for Microscopic Margin Positivity in Basal Cell Carcinoma Excision With a 2-mm Surgical Margin: A Japanese Retrospective Study.

The Journal of dermatology·2025

Same author

Adipose-Derived Stem Cells Alleviate Denervation-Induced Muscle Atrophy by Promoting M2 Macrophage Polarization and Reducing Inflammation.

Muscle & nerve·2025

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

[Development of HDAC inhibitors].

Yoshihiro Sowa¹

¹Dept. of Molecular-Targeting Cancer Prevention, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy

|September 16, 2010

Summary

Epigenetic abnormalities play a key role in cancer development. Histone deacetylase (HDAC) inhibitors are a promising class of anti-tumor drugs with epigenetic effects, showing potential in clinical trials.

Area of Science:

Oncology
Epigenetics
Molecular Biology

Context:

Carcinogenesis involves both genetic and epigenetic abnormalities.
Epigenetic modifications are increasingly recognized as crucial in cancer development.
Histone deacetylase (HDAC) inhibitors represent a class of compounds with demonstrated anti-tumor activity via epigenetic mechanisms.

Purpose:

To review the role of epigenetic abnormalities in carcinogenesis.
To highlight the therapeutic potential of histone deacetylase (HDAC) inhibitors.
To emphasize the need for biomarkers and combination strategies for HDAC inhibitors.

Summary:

Epigenetic abnormalities, alongside genetic mutations, are integral to cancer mechanisms.
Histone deacetylase (HDAC) inhibitors, such as vorinostat and romidepsin, exert anti-tumor effects through epigenetic modulation.

More Related Videos

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Published on: January 14, 2016

Related Experiment Videos

Last Updated: Jun 8, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Published on: January 14, 2016

Several HDAC inhibitors are in clinical trials for monotherapy and combination treatments, building on FDA-approved drugs for cutaneous T-cell lymphoma.

Impact:

Establishes the significance of epigenetic factors in cancer.
Identifies HDAC inhibitors as a key therapeutic strategy.
Underscores the importance of personalized medicine approaches, including biomarker identification and optimized combination therapies, for maximizing the efficacy of HDAC inhibitors in cancer treatment.